Ekso Bionics HLDGS (OTCMKTS:EKSO) Finishes The Week At $1 Per Share
[[tagnumber 0]][[tagnumber 1]]Ekso Bionics HLDGS (OTCMKTS:EKSO) has been trying to recover for quite some time now. The ticker lost a significant amount of its value in the end of 2015 and the beginning of this year, dropping well below the $1 per share mark.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, the market cap of the company has remained rather steep, sitting at more than $100 million. There is, however, a good reason for this and it is revealed by a quick look at the balance sheet of [[tagnumber 6]]EKSO.[[tagnumber 7]] Here are just some of the numbers of prime interest contained in the company’s report for the fiscal 2015.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 11]] [[tagnumber 12]]cash: $19.5 million[[tagnumber 13]] [[tagnumber 12]]current assets: $25.2 million[[tagnumber 13]] [[tagnumber 12]]current liabilities: $8.6 million[[tagnumber 13]] [[tagnumber 12]]revenues: $8.66 million[[tagnumber 13]] [[tagnumber 12]]net loss: $19.6 million[[tagnumber 13]] [[tagnumber 22]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Those numbers are pretty impressive for an OTC marketplace traded entity. [[tagnumber 6]]EKSO,[[tagnumber 7]] however, is not your typical pennystock. The company is a western leader in the niche of exoskeletons that are being used for a wide variety of purposes. Their medical Ekso GT™ exoskeleton was recently cleared for the use with patients suffering from stroke and spinal cord injuries by the FDA.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Furthermore, [[tagnumber 6]]EKSO[[tagnumber 7]] has been involved in DARPA’s Warrior Web project for quite some time now. These are just some of the reasons for which [[tagnumber 6]]EKSO’s[[tagnumber 7]] market valuation seems more adequate than most OTC marketplace stocks out there.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Recently, however, [[tagnumber 6]]EKSO[[tagnumber 7]] has been having a hard time returning above the $1 per share mark. It did manage to stop at exactly $1 in the end of last week, but today’s trading so far shows that the ticker is hesitant to continue up the charts.[[tagnumber 2]]
